Thousands of women with incurable breast cancer thrown a lifeline - doctors say hope is now possible
A trial has found that the drug, vepdegestrant, is twice as effective as existing treatments at extending the lives of patients with incurable breast cancer—buying them precious time with loved ones.
Experts say that vepdegestrant also has far fewer side effects than medicines used on the NHS, and can be taken at home.
One in seven women in the UK are diagnosed with breast cancer in their lifetime—around 56,000 a year—making it the most common cancer in the UK.
While nine out ten patients survive, the disease still claims the lives of more than 11,000 annually.
Around two-thirds of breast cancer patients in the UK have a form of the disease called ER positive HER-2 negative breast cancer.
Of these, up to half with an advanced form can develop a genetic mutation which makes their cancer resistant to treatment.
Patients who get this mutation—called ESR1—typically have less than two years to live.
Currently, these patients receive a once-a-month injection called fulvestrant, which stops cancer cells from feeding off oestrogen, the female sex hormone that research shows helps tumours to grow.
However, fulvestrant, which has to be adminstered by a healthcare professional, has a number of uncomfortable side effects including hot flushes, nausea and muscle pain.
In some cases, it can also damage the liver.
Even then, the injection can only keep the disease at bay for, on average, two months, the trial showed.
And only a fifth of fulvestrant patients go six months without their cancer spreading.
But the vepdegestrant trial, presented at the American Society for Clinical Oncology conference in Chicago, found that the tablet halted the spread of breast cancer for, on average, five months.
Moreover, nearly half of the 300 patients given vepdegestrant went six months without their cancer spreading.
The study found that the drug, which also blocks cancer cells from consuming oestrogen, has no major side effects.
Experts say it is too soon to say exactly how much longer vepdegestrant patients live than those on fulvestrant, but they expect the difference to be significant.
The drug is already being fast-tracked for use in the US and has been sent for approval in the UK.
Experts believe it could get the greenlight in the UK because it is so much better than the existing options.
'Fulvestrant is incredibly painful and uncomfortable for patients, the majority of whom are forced to have to come to the clinic for it,' says Professor Komal Jhaveri, an oncologist at the Memorial Sloan Kettering Cancer Centre in New York.
'Oral tablets can be taken at home.'
Dr Jane Meisel, a medical oncology professor at Emory University in Georgia, said: 'This drug will be a very exciting option for patients that could transform treatment.'
Given it can be taken at home, does not leave patients suffering debilitating side effects, 'it's definitely the first of its kind', she added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
a minute ago
- The Independent
This unbeatable wine deal gets you 12 bottles for just £5.99 each
It's always handy to have a few bottles of wine ready to go in the summer for those last-minute garden parties and barbecues when the sunshine hits. If you need to replenish your stash for the next heatwave, we've spotted an excellent wine deal at Laithwaites. As an introductory offer to its wine case delivery, the retailer is offering 12 bottles of its bestselling reds and whites for just £5.99 each with the discount code 25OFF90. We're always on the lookout for the best wine deals, and this is by far the best offer you'll get on a bulk order of wine right now. As well as bargain bottles, you'll even get some freebies thrown in. This includes a bottle of Cabalié cuvée vieilles (worth £14.99) and Ribolla Gialla spumante cuvée biele zôe (worth £10.99), plus two stemless wine glasses (worth £18) to enjoy your drinks in. For more wine bargains this summer, we've spoken to experts and sommeliers for their pick of the best supermarket wines. If sparkling is more your thing, we've also rounded up the best champagne deals of the month to toast your celebrations. With Laithwaites' welcome offer to its wine subscription, you'll get a mixed case of 12 top-selling bottles, which includes the following red and whites. We've also included how much each bottle would cost if you bought it on its own: Two bottles of Vinha do Fava touriga nacional 2023 (£13.99) Two bottles of Camino de Seda 2023 (£12.49) Two bottles of The Black Stump durif shiraz 2022 (£12.99) Two bottles of Mussel Pot Marlborough sauvignon blanc 2024 (£13.99) Two bottles of Rex Mundi blanc 2024 (£12.99) Two bottles of Alessandro Gallici pinot grigio 2024 (£11.99) Don't forget to use the discount code 25OFF90 to get the bottles for just £5.99 each, totalling £71.82 for the full case. Without the discount code, you'll pay £7.99 per bottle, coming to £95.76 for the full case. Without the offer, you'd pay £156.88 if you bought the wines separately, so you're saving more than 50 per cent when you buy them as part of the deal. If you prefer red wine over white, or vice versa, you can also choose a case of all reds or whites that include more of your chosen type. Keep in mind that when you add this offer to your basket, you're signing up to a regular delivery of the Laithwaites bestsellers case. This means that after eight weeks, you'll be charged £119.88 (£9.99 per bottle) for your next case. If you want to continue the subscription, you can adjust the frequency of delivery to every four or 12 weeks. There's also the option to pause your subscription if you're not ready for another delivery, or cancel for free.
The Independent
a minute ago
- The Independent
Top tips for Gen Z job hunters – and why it's not all doom and gloom
UK unemployment has risen to its highest rate in four years at 4.7 per cent, with job vacancies falling to a decade low of 727,000 between April and June. Young people, especially graduates, are facing the toughest job market since 2018, drawing parallels to the author's experience during the 2008 financial crash. The rise of artificial intelligence is significantly impacting entry-level jobs, with a nearly one-third reduction in such roles since ChatGPT 's launch. Increased labour costs, including higher national insurance contributions and the minimum wage, are also contributing to employers reducing headcounts. Current difficulties are due to economic conditions rather than individual failings.
Scottish Sun
a minute ago
- Scottish Sun
Two NHS drugs slows and could REVERSE devastating Alzheimer's, ‘exciting' study finds
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) TWO NHS drugs could be combined to treat, and even reverse, the most common form of dementia, scientists claim. A pair of cancer drugs have been identified as a powerful duo that may tackle Alzheimer's disease, after scientists sifted through 1,300 approved medicines. Sign up for Scottish Sun newsletter Sign up 1 Alzheimer's was reversed in mice Credit: Alamy The American team used cutting-edge computer tools to match the gene changes seen in Alzheimer's patients with medicines that reverse those effects. They found that two cancer drugs, both already available on the NHS, reduced brain degeneration in mice with the disease, and even brought back their memory. The study, from the University of California, San Francisco (UCSF), first looked at how Alzheimer's alters the activity of individual brain cells. They then searched for existing drugs that trigger the opposite changes, with the aim of rewiring damaged neurons and brain cells called glia. And when they tested the top two candidates, letrozole and irinotecan, in lab mice, the results were impressive. One theory of how Alzheimer's comes about is that sticky proteins - like amyloid-beta - start clumping together in the brain years before symptoms appear. These toxic clumps block communication between brain cells and trigger inflammation, eventually causing the cells to die. Some scientists believe this buildup is the root cause of Alzheimer's, so clearing it could stop the disease in its tracks. When combined, the cancer drugs not only halted brain cell damage but also undid toxic clumps of proteins, restored memory and reversed the disease's genetic footprint. Prof Marina Sirota, senior author, said: 'We're excited that our computational approach led us to a potential combination therapy for Alzheimer's based on existing FDA-approved medications.' Common painkiller used for back pain ups risk of dementia by 29%, scientists warn She added: 'Alzheimer's disease comes with complex changes to the brain, which has made it tough to study and treat — but our tools opened up the possibility of tackling that complexity directly.' The scientists then trawled through the anonymised medical records of 1.4million over-65s and found those already taking the cancer drugs were less likely to develop Alzheimer's. Dr Yaqiao Li, the study's lead author, said: 'Thanks to all these existing data sources, we went from 1,300 drugs, to 86, to 10, to just five. 'In particular, the rich data collected by all the UC health centres pointed us straight to the most promising drugs. It's kind of like a mock clinical trial.' Letrozole is typically used to treat breast cancer, while irinotecan is prescribed for colon and lung cancer. Both are already used in the UK. 'So exciting' Prof Yadong Huang, co-senior author, said: 'Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health. 'This makes it very challenging for drug development - which traditionally produces one drug for a single gene or protein that drives disease.' He added: 'It's so exciting to see the validation of the computational data in a widely used Alzheimer's mouse model.' The breakthrough, published in the journal Cell, could fast-track trials in humans. Prof Sirota said: 'If completely independent data sources, such as single-cell expression data and clinical records, guide us to the same pathways and the same drugs and then resolve Alzheimer's in a genetic model then maybe we're onto something.' She added: 'We're hopeful this can be swiftly translated into a real solution for millions of patients with Alzheimer's.' Alzheimer's causes a relentless decline in cognition, learning, and memory. But decades of research have only produced two FDA-approved drugs, neither of which can meaningfully slow the decline. In the UK, no disease-modifying drugs are currently approved or available. Instead, the UK relies on symptom-managing drugs, such as Donepezil and Rivastigmine.
